Becton Dickinson
BDX
$197.88
-0.23%
Becton, Dickinson and Co. (BDX) is a global medical technology company that manufactures and sells a broad portfolio of medical devices, instrument systems, and reagents, organized into four segments following the separation of its life science business: Medical Essentials (catheters, syringes, infection prevention), Connected Care (Alaris infusion pumps, Pyxis dispensing and pharmacy automation), Biopharma Systems (prefillable syringes and autoinjectors), and Interventional (surgery, peripheral vascular, and urology), with more than 60% of revenue generated in the United States. As one of the largest and most entrenched players in medical instruments and supplies, BDX is a scale-driven, hospital-channel incumbent whose competitive identity rests on deep installed bases, long-term group purchasing relationships, and high switching costs rather than on high-growth innovation cycles. The current investor narrative centers on the post-life-sciences-separation portfolio reshaping, a Q2 FY2026 earnings beat with a raised full-year profit outlook and a newly named CFO, and the debate over whether margin recovery and cash-flow conversion can offset soft top-line trends — most recently underscored by a Q3 FY2026 revenue decline of 9.55% year over year. Analysts remain broadly constructive but cautious, with a consensus 'buy' rating that masks a heavy skew toward Neutral/Sector Perform/Equal Weight stances, reflecting skepticism about the durability of the earnings beat and the pace of operational improvement.…
BDX
Becton Dickinson
$197.88
Related headlines
Investment Opinion: Should I buy BDX Today?
Rating: Hold. The core thesis is that BDX is a high-quality, low-beta defensive medtech franchise whose cash flow and dividend are intact, but whose 27.2% three-month rally to $198.91 has run past the $195.57 analyst average target and priced in a margin recovery that has not yet shown up in revenue, which fell 9.55% YoY in Q3 FY2026.
Supporting the Hold are four data points: a 6.2% FCF yield ($2.606 billion TTM FCF on a $42.2 billion market cap) that comfortably covers the 2.84% dividend at a 71.3% payout ratio; sequential gross margin recovery from 44.63% in Q1 to 46.46% in Q3 FY2026; a forward PE of 14.95x on $16.28 estimated FY EPS, which is not demanding for a medtech incumbent; and a 0.279 beta that makes it a portfolio stabilizer. Against these, revenue is contracting 9.55% YoY, trailing PE is 25.2x on $0.04 EPS, and the consensus recommendation mean of 2.125 is closer to Hold than Buy.
The biggest risks that could invalidate the thesis are a failure of revenue to stabilize in FY2027, a reversal of the margin recovery, and leverage (debt-to-equity 0.755) becoming a problem if rates stay elevated. This Hold would upgrade to Buy if Q4 FY2026 revenue returns to positive YoY growth and gross margin holds above 46%, or if the stock pulls back toward the $165 analyst low; it would downgrade to Sell if revenue declines accelerate beyond 10% or if FCF falls below $2 billion. Valuation verdict: fairly valued to modestly expensive relative to its own history after the rally, and not cheap relative to peers given negative growth.
Sign up to view all
BDX 12-Month Price Forecast
BDX is a defensive, cash-generative medtech franchise trading at a fair 14.95x forward earnings after a 27.2% three-month rally that has taken it to the top of its 52-week range. The bull case depends on revenue stabilizing and margin recovery continuing, while the bear case points to a 9.55% YoY revenue decline and a 25.2x trailing PE on near-zero GAAP EPS. With the analyst average target ($195.57) below the current price and the consensus mean at 2.125, the risk/reward is balanced rather than compelling. I would upgrade to bullish if Q4 FY2026 revenue returns to growth and gross margin holds above 46%, and downgrade to bearish if revenue declines accelerate beyond 10% or FCF falls below $2 billion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $195.57 and implied upside of -1.2% versus the current price.
Average Target
$195.57
0 analysts
Implied Upside
-1.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$165 - $225
Analyst target range
Bulls vs Bears: BDX Investment Factors
The bull case rests on momentum (+27.2% in three months, +24.4 relative strength), a defensive 0.279 beta, a 6.2% FCF yield, and sequential margin recovery from 44.6% to 46.5% gross margin. The bear case is anchored in a 9.55% YoY revenue decline, a trailing PE of 25.2x on near-zero GAAP EPS, a 71.3% payout ratio, and an analyst average target ($195.57) below the current price. On balance, the bear evidence on fundamentals is stronger, but the bull evidence on price action and cash flow is more immediate, making this a fairly balanced debate tilting slightly cautious after the rally. The single most important tension is whether the Q3 revenue decline is a separation-related trough or a structural top-line problem: if revenue returns to growth in FY2027, the 14.95x forward PE is cheap; if it does not, the stock is expensive at 3.13x EV/Sales.
Bullish
- Momentum and relative strength surge: BDX has rallied 27.2% over three months and 30.7% over six months, versus SPY's 2.85% and 6.45% respectively, producing relative strength of +24.4 and +24.3 points. The stock is now at $198.91, within 0.8% of its 52-week high of $200.47, indicating the market is re-rating the post-separation story.
- Analyst targets imply modest upside: The 14-analyst consensus is 'buy' with an average target of $195.57, essentially at the current price, but the high target of $225.00 implies 13.1% upside. Estimated FY EPS of $16.28 against a forward PE of 14.95x suggests the market is not pricing aggressive growth, leaving room for multiple expansion if margin recovery continues.
- Defensive low-beta profile: Beta of 0.279 means BDX has historically moved less than one-third as much as the market, making it a portfolio stabilizer. This defensiveness is corroborated by the stock's 6.6% one-year gain despite a 9.55% YoY revenue decline in Q3 FY2026, showing earnings resilience through top-line pressure.
- Cash generation supports dividend: TTM free cash flow of $2.606 billion against a $42.2 billion market cap implies a 6.2% FCF yield, comfortably covering the 2.84% dividend yield (payout ratio 71.3%). This cash engine funds the dividend and deleveraging even while GAAP earnings are depressed by separation-related charges.
Bearish
- Revenue declining 9.55% YoY: Q3 FY2026 revenue of $4.983 billion fell 9.55% from $5.509 billion a year earlier, and the $21.92 billion consensus FY revenue estimate implies continued contraction. A shrinking top line at a 1.93x PS and 3.13x EV/Sales multiple leaves little room for execution error.
- Earnings quality is weak: Trailing EPS of just $0.04 and a trailing PE of 25.2x reflect heavy separation and restructuring charges, including a Q2 FY2026 net loss of $311 million (EPS -$1.11). The gap between $16.28 estimated FY EPS and $0.04 trailing EPS shows how dependent the story is on non-GAAP adjustments and one-time costs fading.
- Valuation not cheap on cash flow: PCF of 12.3x and EV/EBITDA of 12.2x are full for a company with negative revenue growth, and the negative PEG ratio of -37.0 signals earnings are still below prior-year levels on a GAAP basis. The 2.84% dividend yield with a 71.3% payout ratio also limits flexibility if FCF dips.
- Analyst consensus is soft: Despite a 'buy' label, the recommendation mean of 2.125 (where 1.0 is strong buy and 3.0 is hold) reveals a heavy skew toward Neutral/Sector Perform. The average target of $195.57 is below the current $198.91 price, implying analysts see the stock as fully valued after its 27% three-month run.
BDX Technical Analysis
Beta
0.28
0.28x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$128-$200
Price range past year
Annual Return
+10.3%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | +10.5% | -0.9% |
| 3m | +19.5% | +1.2% |
| 6m | +32.5% | +4.9% |
| 1y | +10.3% | +11.2% |
| ytd | +1.5% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
Quarterly Revenue
$5.0B
2026-06
Revenue YoY Growth
-9.6%
YoY Comparison
Gross Margin
46.5%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
PE
25.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~55x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on a shrinking top line and thin earnings quality. Q3 FY2026 revenue fell 9.55% YoY to $4.983 billion, and the $21.92 billion consensus FY revenue estimate implies further contraction, while trailing EPS of $0.04 and a Q2 net loss of $311 million show how much of the earnings base depends on separation charges fading. Debt-to-equity of 0.755 and a current ratio of 1.11 provide limited buffer, and Q3 interest expense of $132 million absorbs about 20% of the $663 million in operating income, so any margin shortfall flows quickly to the bottom line. The 71.3% payout ratio also leaves little room for FCF disappointment before the 2.84% dividend comes under scrutiny.
Market and competitive risks are dominated by valuation compression after a sharp run. The stock trades at 25.2x trailing earnings, 12.3x cash flow, and 3.13x EV/Sales despite negative revenue growth, and its 27.2% three-month gain has pushed it to within 0.8% of the $200.47 52-week high, meaning much of the recovery is priced in. The analyst average target of $195.57 sits below the current $198.91, and the 2.125 recommendation mean masks a Neutral-heavy consensus, so a single disappointing quarter could trigger downgrades. A beta of 0.279 limits macro-driven drawdowns, but it also means BDX will likely lag in a broad risk-on rotation, as shown by its -6.49 one-year relative strength versus SPY.
In a worst-case scenario, Q4 FY2026 revenue fails to stabilize, separation costs persist into FY2027, and margin recovery reverses, forcing analysts to cut the $16.28 FY EPS estimate and the $195.57 average target toward the $165.00 low. Combined with multiple compression from 14.95x forward earnings toward the low-teens, the stock could retest its 52-week low of $127.59, a decline of roughly 35.8% from $198.91. The historical max drawdown of -33.0% corroborates that a one-third loss is a realistic adverse outcome for this name, and the 5.32 short ratio indicates bears are positioned for exactly that scenario.
FAQ
The most severe risk is revenue deterioration: Q3 FY2026 revenue fell 9.55% YoY, and the $21.92 billion FY consensus implies continued contraction, which would undermine the margin recovery thesis. Second is earnings quality, with trailing EPS of $0.04 and a Q2 FY2026 net loss of $311 million showing heavy dependence on separation charges fading. Third is valuation compression after the 27.2% three-month rally, with the average target of $195.57 below the current $198.91 and a 2.125 recommendation mean skewed to Neutral. Fourth is leverage, with debt-to-equity of 0.755 and Q3 interest expense of $132 million consuming about 20% of operating income, making the company sensitive to refinancing costs. A beta of 0.279 mitigates broad market risk but not company-specific execution risk.
The 12-month outlook has three scenarios. The base case (50% probability) targets $185-$200, assuming revenue declines moderate to low-single-digit negative and EPS holds near the $16.28 consensus, anchoring the stock around the $195.57 average target. The bull case (25%) targets $210-$225, requiring revenue to return to growth and gross margin to hold above 46%, supporting a re-rating toward the $225 high target. The bear case (25%) targets $127.59-$165, driven by revenue declines exceeding 10% and margin reversal, pushing the stock toward the $165 low target and the $127.59 52-week low. The base case is most likely because the 14.95x forward PE and 6.2% FCF yield provide valuation support even without top-line growth.
BDX trades at 25.2x trailing earnings, 14.95x forward earnings, 1.93x sales, and 3.13x EV/Sales. The forward PE of 14.95x on $16.28 estimated EPS is reasonable for a medtech incumbent, but the trailing PE of 25.2x on $0.04 EPS and the 12.3x price-to-cash-flow ratio show the market is paying for a recovery that has not yet appeared in revenue, which fell 9.55% YoY. The negative PEG ratio of -37.0 reflects GAAP earnings still below prior-year levels. Relative to its own history, the stock is at the high end after a 27.2% three-month rally, and the average analyst target of $195.57 sits below the current price. The market appears to be pricing a successful margin recovery and revenue stabilization, leaving limited margin for error.
BDX offers a mixed risk/reward at $198.91. The upside to the $225 high analyst target is 13.1%, but the $195.57 average target is below the current price, and the 2.125 recommendation mean shows analysts are only cautiously constructive. The biggest downside risk is a retest of the $127.59 52-week low, roughly 35.8% below current levels, if revenue declines persist. For income-focused investors, the 2.84% dividend and 6.2% FCF yield are attractive, but growth investors should wait for evidence of revenue stabilization. It is a reasonable defensive holding, not a compelling new buy after a 27.2% three-month run.
BDX is better suited to long-term holding than short-term trading. Its 0.279 beta and 2.84% dividend yield with a 71.3% payout ratio make it a defensive income compounder, and the 6.2% FCF yield supports a multi-year total-return thesis. However, the 9.55% YoY revenue decline and 25.2x trailing PE mean near-term earnings visibility is low, and the 27.2% three-month rally has created short-term valuation risk, with the average target of $195.57 below the current price. A suggested minimum holding period is 18-24 months, allowing separation costs to annualize and revenue to stabilize. Short-term traders should note the stock is within 0.8% of its 52-week high and vulnerable to a pullback toward the $165 analyst low.